| Patent application number | Description | Published |
|---|
| 20090137633 | Stable pharmaceutical composition of rabeprazole - The present invention relates to a method of preparing a stable pharmaceutical composition of rabeprazole. The preparation may be used as an injectable dosage form in the treatment of severe gastric ulcers. | 05-28-2009 |
| 20090177008 | NOVEL PROCESS FOR SYNTHESIS OF ITOPRIDE AND ITS NOVEL INTERMEDIATE N-(4-HYDROXYBENZYL)- 3,4-DIMETHOXYBENZAMIDE - The present invention relates to a novel and improved process for the preparation of N-[4-[2-(dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide—known as Itopride, via a novel intermediate N-(4˜hydroxybenzyl)-3,4-dimethoxybenzamide. | 07-09-2009 |
| 20100062026 | POLY TLR ANTAGONIST - w or its components are found to have poly TLR antagonistic activity to induced TLRs by varieties of TLR ligands. The induced TLR against which inhibitory effect is seen includes TLR 3, 4, 5, 6, 7, 8, 9. They also display antagonistic activities to effects of TLR ligands. They are also useful in management of diseases wherein TLRs are over expressed, like sepsis, multiple sclerosis, optic neuritis, Chronic obstructive pulmonary diseases multiple myeloma etc. | 03-11-2010 |
| 20100104536 | P38 INHIBITORS - The invention relates to novel p38 MAPK inhibitor which involves | 04-29-2010 |
| 20100113802 | PROCESS FOR PREPARING AMORPHOUS ATORVASTATIN HEMI CALCIUM SALT AND ITS ITERMEDIATE - The invention relates to the HMG-CoA reductase inhibitor in particular to Atorvastatin Hemi-calcium. The present invention is directed to novel processes for preparing amorphous form of Atorvastatin hemi calcium and their intermediate in high purity. | 05-06-2010 |
| 20100209394 | MITOGEN ACTIVATED PROTEIN KINASE MODULATOR - The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacterium w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions. | 08-19-2010 |
| 20110020440 | STABLE SOLUTIONS OF SPARINGLY SOLUBLE ACTIVES - The present invention relates to a stable pharmaceutical composition comprising soft gelatin capsules containing at least one sparingly soluble active drug (singly or in combination with sparingly soluble and/or soluble drugs) and a solvent system, wherein the solvent system comprises of solvent, co-solvent, solubilizer(s), surfactant, aqueous solution of alkali and crystal growth inhibitor. The present invention further relates to process for preparing a stable pharmaceutical composition of sparingly soluble active drug(s) in soft gelatin capsules. | 01-27-2011 |
| 20110182939 | Vaccine Adjuvants - The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response. | 07-28-2011 |
| 20110183919 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS - The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme. | 07-28-2011 |
